Prostate Cancer Coverage from Every Angle
Editor:
Sandy Srinivas, MD
Advertisement
Advertisement

Available Clinical Trials

A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects
The University of Alabama at Birmingham Comprehensive Cancer Center
City of Hope
Dana-Farber Cancer Institute
DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Duke Cancer Institute
Fox Chase Cancer Center
Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance
Helen Diller Family Comprehensive Cancer Center
Huntsman Cancer Institute
Massachusetts General Hospital Cancer Center
Mayo Clinic
MD Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Moffitt Cancer Center
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer
PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Seidman Cancer Center
Siteman Cancer Center
Stanford Cancer Institute
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
The Ohio State University Comprehensive Cancer Center
The Sidney Kimmel Comprehensive Cancer Center
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
UC San Diego Health Moores Cancer Center
University of Colorado Cancer Center
University of Michigan Comprehensive Cancer Center
University of Nebraska
University of Wisconsin Carbone Cancer Center
Vanderbilt-Ingram Cancer Center
Yale Cancer Center
Copyright © 2022 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.